See our work in action with these real-world examples.
Following the EC Recommendation 2013/473/EU, companies who do not design or manufacture the devices were to use the term “manufacturer”.
To authorise the exceptional use of a medicinal product that has not yet been granted marketing authorisation (MA). Such option is covered at European Community level in Article 5(1) of Directive 2001/83/EC, duly amended.
EUDRAC held a 2-day pharmacovigilance inspection by the German Competent Authority (BfArM).
Update an established Risk Management Plan (RMP) in the Revision 1 template to the Revision 2 template.
To perform a Periodic Safety Update Report (PSUR) in the European Union for a product which was not registered in the eXtended Medicinal Product Dictionary (XEVMPD) after recent marketing authorisation transfer.
Provide a full project management and regulatory function for a Centralised MAA for a virtual pharmaceutical company.
EUDRAC works with The EspeRare Foundation on a PRIME application for an orphan drug
Obtain CHMP’s agreement on a change in development plan previously agreed.
Post a regular pharmacovigilance inspection by a European Union (EU) National Competent Authority, a pharmaceutical company received a major inspection. The finding stated the requirement to regularly review and document changes in pharmaceutical regulations and guidance.
This website uses cookies to ensure you get the best experience on our website. Read more. Got it